Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic analog of parathyroid hormone-related protein (PTHrP) FDA-approved for osteoporosis. Similar to teriparatide but with a potentially more favorable bone-building to bone-resorbing ratio and lower hypercalcemia risk.
A recombinant fragment of parathyroid hormone (amino acids 1-34) FDA-approved for osteoporosis. The first anabolic (bone-building) agent approved for osteoporosis, as opposed to anti-resorptive drugs that only slow bone loss.
Selectively activates the RG conformation of the PTH1 receptor, producing a more transient signaling response than teriparatide. This results in robust bone formation with less bone resorption and less calcium mobilization from bone.
Intermittent exposure to PTH(1-34) paradoxically stimulates osteoblast activity more than osteoclast activity, resulting in net bone formation. This is opposite to the bone-resorbing effect of continuously elevated PTH in hyperparathyroidism.
- Postmenopausal osteoporosis
- Fracture risk reduction
- Bone density improvement
- Severe osteoporosis
- Fracture risk reduction
- Glucocorticoid-induced osteoporosis
- Bone healing acceleration
- Osteosarcoma risk (boxed warning — animal studies)
- Dizziness
- Nausea
- Tachycardia
- Injection site reactions
- Limited to 2 years of use
- Osteosarcoma risk (boxed warning — based on rat studies at high doses)
- Hypercalcemia
- Orthostatic hypotension
- Leg cramps
- Nausea
- Limited to 2 years of use
FDA-approved as Tymlos (2017) for treatment of postmenopausal women with osteoporosis at high fracture risk. Limited to 2 years. Pen injector for daily self-administration.
FDA-approved as Forteo (2002) for osteoporosis in postmenopausal women and men at high fracture risk. Limited to 2 years of treatment due to theoretical osteosarcoma risk. Biosimilar (Tymlos/abaloparatide is a related but distinct peptide).
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.